Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR
(Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC
lung disease. This study will enroll adult patients with treatment-refractory MAC lung
disease who meet all eligibility criteria (including clinical, radiographic, and
microbiological criteria).